Bolt Biotherapeutics Inc expected to post a loss of 38 cents a share - Earnings Preview

Bolt Biotherapeutics

17/03/2025 11:02

Bolt Biotherapeutics Inc BOLT.OQ BOLT.O is expected to show a fall in quarterly revenue when it reports  results on March 19 (estimated) for the period ending December 31 2024

The Redwood City California-based  company is expected to report a 62.2% decrease in revenue to $790 thousand from $2.09 million a year ago, according to the mean estimate from 3 analysts, based on LSEG data.

​LSEG's mean analyst estimate for Bolt Biotherapeutics Inc is for a loss of 38 cents per share.

The current average analyst rating on the shares is "hold" and the breakdown of recommendations is no "strong buy" or "buy," 4 "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts was unchanged in the last three months. ​

Wall Street's median 12-month price target for Bolt Biotherapeutics Inc is $1.75​, above​ its last closing price of $0.41. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Sep. 30 2024
-0.34
-0.35
-0.40
Missed
-13.5
Jun. 30 2024
-0.52
-0.48
-0.46
Beat
4.2
Mar. 31 2024
-0.50
-0.51
-0.28
Beat
45.1​
Dec. 31 2023
-0.44
-0.48
-0.47
Beat
2.4
​​Sep. 30 2023
-0.50
-0.50
-0.43
Beat
14
Jun. 30 2023
-0.50
-0.49
-0.48
Beat
1.4​
Mar. 31 2023
-0.51
-0.51
-0.45
Beat
12.1
Dec. 31 2022
-0.60
-0.53
Beat
11.4

This summary was machine generated March 17 at 11:01 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)